公开(公告)号：US11052131B2

公开(公告)日：2021-07-06

申请号：US16339931

申请日：2017-10-04

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  UNIVERSITE DE BORDEAUX ,  INSTITUT BERGONIÉ

发明人： Géraldine Siegfried ,  Abdel-Majid Khatib ,  Jean-Luc Hoepffner ,  Serge Evrard

IPC分类号： A61K38/22 ,  A61P35/00 ,  C07K14/575

摘要： Disclosed are methods and pharmaceutical compositions for the treatment of kidney cancer. The inventors showed that while Elabela (ELA) is mostly expressed in kidney, its expression is reduced in human kidney cancer. In a xenograft animal model (sub-cutaneous, or sub-capsular injection) Ela inhibits tumor progression. In particular, there is disclosed a method of treating kidney cancer in a subject in need thereof including administering to the subject a therapeutically effective amount of an ELA polypeptide including an amino acid sequence having at least 90% of identity with SEQ ID NO: 1 (QRPVNLTMRRKLRKHNCLQRRCMPLHSRVPFP) wherein the arginine residue (R) at position 9, 10, 20 or 21 is optionally mutated.

公开(公告)号：US10556941B2

公开(公告)日：2020-02-11

申请号：US16156521

申请日：2018-10-10

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  UNIVERSITÉ DE BORDEAUX ,  UNIVERSITÉ DE RENNES ,  ECOLE DES HAUTES ETUDES EN SANTÉ PUBLIQUE (EHESP) ,  UNIVERSITÉ DES ANTILLES ET DE LA GUYANE ,  INSTITUT BERGONIÉ ,  UNIVERSITY OF NOTTINGHAM

发明人： Patrick Legembre ,  Pierre Vacher ,  Doriane Sanseau ,  Aubin Penna ,  Robin Flynn

IPC分类号： C07K14/70 ,  A61K38/00 ,  C07K14/705 ,  C07K14/525 ,  C07K16/00 ,  G01N33/68

摘要： The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid residue at position 191 in SEQ ID NO:1.

公开(公告)号：US20200030413A1

公开(公告)日：2020-01-30

申请号：US16339931

申请日：2017-10-04

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  UNIVERSITE DE BORDEAUX ,  INSTITUT BERGONIÉ

发明人： Géraldine SIEGFRIED ,  Abdel-Majid KHATIB ,  Jean-Luc HOEPFFNER ,  Serge EVRARD

IPC分类号： A61K38/22 ,  A61P35/00

摘要： Disclosed are methods and pharmaceutical compositions for the treatment of kidney cancer. The inventors showed that while Elabela (ELA) is mostly expressed in kidney, its expression is reduced in human kidney cancer. In a xenograft animal model (sub-cutaneous, or sub-capsular injection) Ela inhibits tumor progression. In particular, there is disclosed a method of treating kidney cancer in a subject in need thereof including administering to the subject a therapeutically effective amount of an ELA polypeptide including an amino acid sequence having at least 90% of identity with SEQ ID NO: 1 (QRPVNLTMRRKLRKHNCLQRRCMPLHSRVPFP) wherein the arginine residue (R) at position 9, 10, 20 or 21 is optionally mutated.

公开(公告)号：US20190350907A1

公开(公告)日：2019-11-21

申请号：US16478520

申请日：2018-01-15

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE RENNES 1 ,  UNIVERSITÉ DE BORDEAUX ,  INSTITUT BERGONIÉ ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  CHU DE BORDEAUX

发明人： Patrick LEGEMBRE ,  Pierre VACHER ,  Amanda POISSONNIER ,  Patrick BLANCO

IPC分类号： A61K31/427 ,  A61K31/603 ,  A61K31/085 ,  A61K31/4439 ,  A61K31/704

摘要： The present invention relates to a method for reducing CD95-mediated cell motility. To identify chemicals disrupting CD95/PLCγ1 interaction, the inventors screened a chemical library of EMA/FDA-approved molecules against a protein-fragment complementation assay (PCA) monitoring the binding of CD95 to PLCγ1. From this screen, five chemical molecules showed the ability to disrupt CD95/PLCγ1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells. Thus, the present invention relates to a method for reducing CD95-mediated cell motility, comprising administering the subject with at least one compound selected from the group consisting of HIV-protease inhibitors (e.g. ritonavir), diflunisal, anethole, rosiglitazone and daunorubicin. Particularly, the method of the invention find use in the treatment of cancer such as triple negative breast cancer, autoimmune inflammatory disease such as systemic lupus erythematosus, inflammatory condition and Th17-mediated disease.

公开(公告)号：US20190085050A1

公开(公告)日：2019-03-21

申请号：US16156521

申请日：2018-10-10

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE BORDEAUX ,  UNIVERSITÉ DE RENNES ,  ECOLE DES HAUTES ETUDES EN SANTÉ PUBLIQUE (EHESP) ,  UNIVERSITÉ DES ANTILLES ET DE LA GUYANE ,  INSTITUT BERGONIÉ ,  UNIVERSITY OF NOTTINGHAM

发明人： Patrick LEGEMBRE ,  Pierre VACHER ,  Doriane SANSEAU ,  Aubin PENNA ,  Robin FLYNN

IPC分类号： C07K14/705 ,  G01N33/68 ,  C07K14/525 ,  C07K16/00 ,  A61K38/00

CPC分类号： C07K14/70575 ,  A61K38/00 ,  C07K14/525 ,  C07K16/00 ,  C07K2319/74 ,  G01N33/6872 ,  G01N2333/70575 ,  G01N2333/70578 ,  G01N2500/02

摘要： The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid residue at position 191 in SEQ

公开(公告)号：US10189887B2

公开(公告)日：2019-01-29

申请号：US15304550

申请日：2015-04-16

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE BORDEAUX ,  UNIVERSITÉ DE RENNES ,  ECOLE DES HAUTES ETUDES EN SANTÉ PUBLIQUE (EHESP) ,  UNIVERSITÉ DES ANTILLES ET DE LA GUYANE ,  INSTITUT BERGONIÉ ,  UNIVERSITY OF NOTTINGHAM

发明人： Patrick Legembre ,  Pierre Vacher ,  Doriane Sanseau ,  Aubin Penna ,  Robin Flynn

IPC分类号： C07K14/70 ,  C07K16/00 ,  C07K14/705 ,  C07K14/525 ,  G01N33/68 ,  A61K38/00

摘要： The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid residue at position 191 in SEQ ID NO:1.

公开(公告)号：US20170044234A1

公开(公告)日：2017-02-16

申请号：US15304550

申请日：2015-04-16

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE BORDEAUX ,  UNIVERSITÉ DE RENNES ,  ECOLE DES HAUTES ETUDES EN SANTÉ PUBLIQUE (EHESP) ,  UNIVERSITÉ DES ANTILLES ET DE LA GUYANE ,  INSTITUT BERGONIÉ ,  UNIVERSITY OF NOTTINGHAM

发明人： Patrick LEGEMBRE ,  Pierre VACHER ,  Doriane SANSEAU ,  Aubin PENNA ,  Robin FLYNN

IPC分类号： C07K14/705 ,  G01N33/68 ,  C07K16/00

CPC分类号： C07K14/70575 ,  A61K38/00 ,  C07K14/525 ,  C07K16/00 ,  C07K2319/74 ,  G01N33/6872 ,  G01N2333/70575 ,  G01N2333/70578 ,  G01N2500/02

摘要： The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid residue at position 191 in SEQ ID NO:1.

摘要翻译： 本发明涉及多肽及其用于减少CD95-沉默的细胞运动性的用途。 具体地说，本发明涉及一种多肽，其氨基酸序列与氨基酸序列具有至少70％的同一性，其氨基酸序列范围从SEQ ID NO中的第175位的氨基酸残基至第191位的氨基酸残基 ：1。